Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 18, 2006. The report details a specific corporate action regarding the repurchase of the company's own ordinary shares.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share repurchase transaction:
- Shares Purchased: 175,000 ordinary shares of 25 pence each.
- Purchase Price: 1,474.8457 pence per share.
- Total Treasury Shares: 200,721,678 shares held in Treasury following the transaction.
- Shares in Issue: 5,785,981,304 shares (excluding Treasury shares).
Material Changes
The material change reported is the reduction of outstanding shares through a buyback program authorized by shareholders at the Annual General Meeting on May 17, 2006. The company executed the purchase on October 18, 2006, and intends to hold the acquired shares in Treasury.
Guidance, Outlook, and Risks
The filing contains no management commentary, future guidance, outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase or subscribe for securities in any jurisdiction.
Key Facts for Investor Verification
- Verify the total cost of the repurchase by multiplying 175,000 shares by the price of 1,474.8457 pence.
- Confirm the updated share capital structure: 5,785,981,304 shares in issue versus 200,721,678 shares in Treasury.
- Note that this transaction was executed under authority granted at the May 17, 2006 Annual General Meeting.